Safety labelling changes have been made in the US and UK for the Respiratory Syncytial Virus (RSV) vaccines Abrysvo (Pfizer Inc.) and Arexvy (GlaxoSmithKline Biologicals). Both vaccines will now include a warning about the potential risk of Guillain-Barré syndrome (GBS) following administration. Updated Safety Warnings: GBS is a rare but serious autoimmune disorder in which…
Category: Neuroimmunology
Immune response responsible for neurological damage
There has been a long-held belief that acute viral infections are directly responsible for neurological damage, but researchers from McMaster University have now discovered that it is the immune system’s response that is behind it. The research, published on February 5, 2024 in Nature Communications, was led by Elizabeth Balint, a PhD student at McMaster, and…
CIDP – FDA approval of HYQVIA
FDA approves Takeda’s Immune Globulin Infusion, Hyqvia 16 January, 2024; The U.S. Food and Drug Administration (FDA) has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults. HYQVIA first received approval…
